NCT02196506 - Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress | Biotech Hunter

Enrollment

837

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions

Depressive DisorderDepressionDepressive Disorder, MajorMood DisordersMental Disorders

Interventions

DRUG

Placebo + ADT

Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)

DRUG

Brexpiprazole +ADT

Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)

Trial Locations (47)

Unknown

Birmingham

Beverly Hills

Denver

Hialeah

Orlando

Alpharetta

Smyrna

Baltimore

Boston

Rochester Hills

Cherry Hill

Jamaica

New York

Staten Island

Raleigh

Cincinnati

Edmond

Portland

Salem

Philadelphia

Lincoln

Columbia

Memphis

Wichita Falls

Murray

Woodstock

Charlottesville

Richmond

Seattle

Spokane

Achim

Berlin

Düsseldorf

Frankfurt

Freiburg im Breisgau

Oranienburg

Stralsund

Würzburg

Budapest

Győr

Gdansk

Lubin

Sosnowiec

Warsaw

Bratislava

Kosice-Barca

Liptovský Mikuláš

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY